#USA #Minneapolis #PFAS #Claros Technologies #Bachem AG

Claros Technologies Expands Operations in Europe

Introduction

Claros Technologies, a globally recognized leader in PFAS (Per- and Polyfluoroalkyl Substances) destruction technology, has recently announced a significant milestone in its business journey by entering the pharmaceutical manufacturing sector in Europe. This strategic move follows the success of a pilot project utilizing their innovative ClarosTechUV™ system at the Bachem AG production site in Bubendorf, Switzerland.

Pilot Project Overview

The pilot project at Bachem AG, a prominent global producer of peptide and oligonucleotide-based active pharmaceutical ingredients (APIs), showcased the capabilities of the ClarosTechUV™ technology. Over two weeks of real-world production testing, the system not only met but exceeded Bachem's performance criteria for trifluoroacetic acid (TFA) destruction, a short-chain PFAS.

This collaboration highlights Claros’ versatility and positions the company favorably within the ever-evolving pharmaceutical landscape, where the safe disposal of PFAS in wastewater has become critical amid increasing regulatory scrutiny.

Significance in Pharmaceutical Production

Bachem AG focuses on developing and manufacturing vital APIs, including semaglutide, which is widely used in GLP-1 treatments for weight management and type 2 diabetes. The clear success of the pilot program underscores how Claros’ technology can play an integral role in responsible pharmaceutical manufacturing, especially in the context of rising environmental concerns surrounding PFAS management.

Advancements in Handling PFAS

As regulatory pressure mounts around compounds like TFA, which are gaining attention in both Europe and the U.S., Claros Technologies is poised to help manufacturers meet these challenges. The European authorities are currently exploring broader PFAS restrictions under the REACH regulations, while the U.S. EPA aims to monitor TFA in drinking water under the sixth Unregulated Contaminant Monitoring Rule (UCMR 6).

During this regulatory transition, Bachem’s proactive implementation of the ClarosTechUV™ system places the company at the forefront of sustainable practices in pharmaceutical manufacturing.

Technical Aspects of ClarosTechUV™

The ClarosTechUV™ system is tailored for high-throughput industrial operations and is designed to seamlessly integrate into existing industrial wastewater treatment processes. Unlike traditional PFAS treatment technologies that often only encapsulate PFAS compounds in secondary waste streams, ClarosTechUV™ effectively destroys these persistent substances at their source. This patented system utilizes a high-throughput photochemical UV process to achieve significant destruction rates of over 99.99% for targeted PFAS species, including ultra-short-chain variants like TFA.

In the pilot project, Bachem reported that post-treatment, minimal residual traces of TFA were detectable in their industrial wastewater, emphasizing the effectiveness of their approach. This aligns with statements made by Bachem’s communication head Patrick Barth, who noted that the collaboration is part of their larger commitment to reducing TFA levels in pharmaceutical manufacturing processes.

The Future of Pharmaceutical Manufacturing

The pilot project serves as a critical data point for future engineering decisions aimed at commercializing the destroyer system across diverse manufacturing sites. According to André Casagrande, the Bachem campus head, the collaboration with Claros reflects a broader ethos within the company, merging innovation with environmental responsibility.

Conclusion

As Claros Technologies continues its expansion into the European market, it brings to the forefront vital technologies that facilitate a responsible approach to pharmaceutical manufacturing, specifically targeting critical challenges posed by PFAS substances. With the ongoing growth in peptide treatments and a firm commitment to sustainable practices, it is evident that collaborations like that of Claros and Bachem AG will play a pivotal role in the pharmaceutical industry's efforts towards environmental stewardship and regulatory compliance. This partnership sets a benchmark for the rest of the industry, showcasing best practices in managing essential chemicals while adhering to an eco-friendly framework.

For more information on Claros Technologies, visit their official site.